Key result
Speckle tracking echocardiography demonstrated incremental value in distinguishing cardiac amyloidosis from hypertrophic cardiomyopathy.
Why the study?
Does speckle tracking echocardiography help differentiate cardiac amyloidosis from hypertrophic cardiomyopathy?
Case Report
Does speckle tracking echocardiography help differentiate cardiac amyloidosis from hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Speckle tracking echocardiography is a useful adjunctive non-invasive tool for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy.
Cardiac Amyloidosis (CA) often requires multiple diagnostic modalities with echocardiogram being the most important non-invasive method. Echocardiographic findings of left ventricular hypertrophy (LVH), impaired relaxation and dilated atrias can be seen in others forms of LVH like hypertrophic cardiomyopathy (HCM). Speckle tracking echocardiography (STE), is a relatively new advancement in echocardiography which makes it possible to assess the deformation of the left ventricle and can be utilized for differentiating CA from other forms of LVH. We demonstrate the incremental value provided by STE in distinguishing CA from HCM.
No takes yet. Share an insight, caveat, or question.
Nandakumar et al. (2017) conducted a case report in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. Speckle tracking echocardiography (STE) was evaluated on Differentiating Cardiac Amyloidosis from Hypertrophic Cardiomyopathy. Speckle tracking echocardiography demonstrated incremental value in distinguishing cardiac amyloidosis from hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: